It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Myoglobin, encoded by MB, is a small cytoplasmic globular hemoprotein highly expressed in cardiac myocytes and oxidative skeletal myofibers. Myoglobin binds O2, facilitates its intracellular transport and serves as a controller of nitric oxide and reactive oxygen species. Here, we identify a recurrent c.292C>T (p.His98Tyr) substitution in MB in fourteen members of six European families suffering from an autosomal dominant progressive myopathy with highly characteristic sarcoplasmic inclusions in skeletal and cardiac muscle. Myoglobinopathy manifests in adulthood with proximal and axial weakness that progresses to involve distal muscles and causes respiratory and cardiac failure. Biochemical characterization reveals that the mutant myoglobin has altered O2 binding, exhibits a faster heme dissociation rate and has a lower reduction potential compared to wild-type myoglobin. Preliminary studies show that mutant myoglobin may result in elevated superoxide levels at the cellular level. These data define a recognizable muscle disease associated with MB mutation.
Myoglobin is a hemeprotein that reversibly binds oxygen and gives muscle its red color. Here, the authors report a genetic variant in the MB gene that associates with myoglobinopathy, an autosomal dominant progressive myopathy, and altered oxygen binding properties of the mutant protein.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 IDIBELL-Hospital de Bellvitge, Hospitalet de Llobregat, Neuropathology Unit, Department of Pathology and Neuromuscular Unit, Department of Neurology, Barcelona, Spain (GRID:grid.417656.7)
2 Karolinska Institutet, Department of Molecular Medicine and Surgery, Science for Life Laboratory, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Centre for Inherited Metabolic Diseases, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
3 Centre for Medical Research, University of Western Australia, Harry Perkins Institute of Medical Research, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
4 Hospital Universitario Virgen del Rocío, Neurology Department and Instituto de Biomedicina de Sevilla, Seville, Spain (GRID:grid.411109.c) (ISNI:0000 0000 9542 1158)
5 Karolinska Institutet, Department of Biosciences and Nutrition, Science for Life Laboratory, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Clinical Research Centre, Huddinge, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
6 University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy (GRID:grid.7548.e) (ISNI:0000000121697570)
7 University of Modena and Reggio Emilia, Department of Chemical and Geological Sciences, Modena, Italy (GRID:grid.7548.e) (ISNI:0000000121697570)
8 The University of Western Australia, School of Molecular Sciences, Crawley, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
9 ALBA Synchrotron Light Source, Cerdanyola del Vallès, Barcelona, Spain (GRID:grid.423639.9)
10 BOKU—University of Natural Resources and Life Sciences, Division of Biochemistry, Department of Chemistry, Vienna Institute of BioTechnology, Vienna, Austria (GRID:grid.5173.0) (ISNI:0000 0001 2298 5320)
11 The University of Western Australia, School of Human Sciences, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910)
12 The University of Western Australia, School of Human Sciences, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910); Victor Chang Cardiac Research Institute, Darlinghurst, Australia (GRID:grid.1057.3) (ISNI:0000 0000 9472 3971)
13 Universitat Autònoma de Barcelona, Unitat de Biofísica, Departament de Bioquímica i de Biologia Molecular, Facultat de Medicina, Bellaterra, Spain (GRID:grid.7080.f)
14 Karolinska University Hospital, Solna, Department of Molecular Medicine and Surgery, Karolinska Institutet, and Department of Clinical Genetics, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705)
15 Karolinska Institutet, Department of Women’s and Children’s Health, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
16 Karolinska University Hospital, Centre for Inherited Metabolic Diseases, Stockholm, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
17 Hospital Son Espases, Neurology Department, Palma de Mallorca, Spain (GRID:grid.411164.7) (ISNI:0000 0004 1796 5984)
18 Hospital Verge de la Cinta, Neurology Department, Tortosa, Spain (GRID:grid.411164.7)
19 Université Sorbonne, UPMC Univ Paris 06, INSERM; UMRS974, CNRS FRE3617, Center for Research in Myology, GH Pitié-Salpêtrière, Paris, France (GRID:grid.411164.7); Centre de Référence de Pathologie Neuromusculaire Paris-Est, Institut de Myologie, GHU Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
20 Université Sorbonne, UPMC Univ Paris 06, INSERM; UMRS974, CNRS FRE3617, Center for Research in Myology, GH Pitié-Salpêtrière, Paris, France (GRID:grid.50550.35); Centre de Référence de Pathologie Neuromusculaire Paris-Est, Institut de Myologie, GHU Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
21 Centre de Pathologie et Neuropathologie Est, Hospices Civils de Lyon; Université Claude Bernard Lyon1, Institut NeuroMyogène CNRS UMR 5310—INSERM U1217; Institut NeuroMyogène, Villeurbanne, France (GRID:grid.462834.f)
22 Electromyographie—Groupement Hospitalier Est, Hospices Civils de Lyon, France (GRID:grid.413852.9) (ISNI:0000 0001 2163 3825)
23 University Hospitals Leuven, Department of Neurology, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338); KU Leuven—University of Leuven, Laboratory for Muscle diseases and Neuropathies, Department of Neurosciences, Experimental Neurology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
24 Leiden University Medical Center, Department of Neurology, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000000089452978)
25 KU Leuven—University of Leuven, Laboratory for Neuroimmunology, Department of Neurosciences, Experimental Neurology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
26 Antwerp University Hospital, Department of Pathology, Edegem, Belgium (GRID:grid.411414.5) (ISNI:0000 0004 0626 3418); University of Antwerp, Laboratory of Neuromuscular Pathology, Institute Born-Bunge, Wilrijk, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681); Radboud University Medical Center, Department of Pathology, Nijmegen, The Netherlands (GRID:grid.10417.33) (ISNI:0000 0004 0444 9382)
27 Neuromuscular Reference Center, Henri Mondor University Hospital AP-HP, INSERM U955, Team 10, Biology of the Neuromuscular System, East-Paris University (UPEC), Paris, France (GRID:grid.462410.5) (ISNI:0000 0004 0386 3258)
28 Karolinska Institutet, Department of Biosciences and Nutrition, Science for Life Laboratory, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Karolinska University Hospital, Clinical Research Centre, Huddinge, Sweden (GRID:grid.24381.3c) (ISNI:0000 0000 9241 5705); University of Helsinki and Folkhälsan Institute of Genetics, Molecular Neurology Research Program, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); King’s College London, School of Basic and Medical Biosciences, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
29 Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
30 University of Tampere, Neuromuscular Research Center, Tampere University Hospital, Tampere, Finland (GRID:grid.502801.e) (ISNI:0000 0001 2314 6254); Folkhälsan Genetic Institute, University of Helsinki, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071); Tampere University Hospital, University of Tampere, Neurology Department, Vasa Central Hospital, Vasa, Finland Neuromuscular Research Center, Tampere, Finland (GRID:grid.417201.1) (ISNI:0000 0004 0628 2299)
31 IDIBELL-Hospital de Bellvitge, Hospitalet de Llobregat, Neuropathology Unit, Department of Pathology and Neuromuscular Unit, Department of Neurology, Barcelona, Spain (GRID:grid.417656.7); University of Barcelona, CIBERNEDHospitalet de LLobregat, Department of Pathology and Experimental Therapeutics, Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247)
32 Center for Molecular Medicine, Karolinska Institutet, Stockolm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)